Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad Genetics' Colaris

This article was originally published in The Gray Sheet

Executive Summary

Hereditary colon and endometrial cancer predictive medicine test is slated for launch in September, the firm announces. The test is used to assess an individual's risk of cancer based on the presence of a mutation in either of two genes, the firm explains. Myriad will begin accepting samples for testing nationwide next month. The test will be sold in the U.S. by the firm's existing 40-person oncology product sales force. Worldwide product rollout of the molecular diagnostic test will follow U.S. introduction
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel